Proteonomix, Inc. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, is pleased to provide an update on Proteonomix’s successful international approach to commercializing its proprietary and patent pending stem cell technologies. In the past few months